IN THE NEWS

THE LATEST NEWS

Untitled design 1
Oct 14, 2022

Intelligent Technology Brings Companies To A New Moment Of Truth

Aug 23, 2017

BioCentury highlights GNS-Alexion partnership

Aug 21, 2017

FierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases

Aug 20, 2017

Rare Disease Report Covers Alexion-GNS REFS Licensing Agreement

Aug 18, 2017

GNS Co-Founder Iya Khalil Interviewed in The Pink Sheet

Aug 10, 2017

GNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases

Jun 19, 2017

GNS Healthcare Announces Collaboration to Power Cancer Drug Development with REFS™ Causal Machine Learning and Simulation AI Platform

May 31, 2017

GNS Healthcare Uncovers Novel Targets for Triple-Negative Breast Cancer Using Causal Machine Learning and Simulation Platform REFS™

Dec 07, 2016

GenomeWeb Article Offers Insight on GNS-Celgene Deal and Growing Demand for Causal Modeling

Dec 06, 2016

Outsourcing Pharma Puts Spotlight on Power of Causality, Highlights GNS-Celgene Deal Licensing REFS